WL Gore & Associates (Gore) has announced the first Gore Viafort Vascular Stent implants in patients at Auckland City Hospital, New Zealand. 

The implant procedures were performed by Auckland Regional Public Health Service Regional Interventional Radiology director Dr Andrew Holden and completed as part of the multicentre and non-randomised single-arm Gore Viafort Device Pivotal Clinical Study.

The vascular stent is intended to treat inferior vena cava (IVC) occlusive disease with or without the involvement of the iliofemoral vein.

Holden said: “This first implantation is an important milestone for venous occlusive disease treatment.

“Right now, there are limited device options indicated for both IVC and iliofemoral venous disease. Implanting the Gore Viafort Vascular Stent in patients represents a significant step forward in research.”

The US Food and Drug Administration (FDA) previously granted Breakthrough Device designation for the vascular stent, which uses Gore’s expanded polytetrafluoroethylene (ePTFE) technology as well as a single-wound nitinol frame.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

A clinical study assessing the stent in a treatment range of 10mm to 28mm diameter for iliofemoral veins and inferior vena cava is currently underway in the US.

Gore Peripheral Business leader Jill Paine said: “We are excited to explore the Gore Viafort Vascular Stent in people experiencing IVC occlusive disease.

“At Gore, we strive to build on our legacy of deliberate innovation and prioritise research that addresses unmet needs so we truly can help improve life.”

Last August, Gore reported that five-year data from the study of its GORE EXCLUDER Iliac Branch Endoprosthesis (IBE) for endovascular repair of iliac aneurysms confirmed its safety.

The prospective, multicentre trial established the efficacy and durability of the IBE in treating aortoiliac and iliac artery aneurysms.